- Grants since 2016
- 145
- Awarded, last 5 years (where amounts are published)
- $500k
- Funded works, last 5 years
- 1 228
- Funded works, all time
- 2 889
Grants
2017–2020 · research · SU2C CATALYST® RESEARCH TEAM WITH SUPPORT FROM BRISTOL MYERS SQUIBB
Combined Approaches by Immune Checkpoint Inhibition for Hypermutant Cancers
Uri Y. Tabori · Hospital for Sick Children
2017 · research · SU2C Innovative Research Grant (Class of 2017)
DELINEATING THE ROLE OF THE MICROBIOME IN MODULATING TUMOR AND HOST IMMUNITY
Jennifer A. Wargo · The University of Texas MD Anderson Cancer Center
2016 · research · SU2C Innovative Research Grant (Class of 2016)
DEUBIQUITINATING ENZYMES AS NOVEL ANTICANCER TARGETS
2016 · research · SU2C Innovative Research Grant (Class of 2016)
IMAGING CELL-LEVEL HETEROGENEITY IN SOLID TUMORS FOR PERSONALIZED TREATMENT
Melissa C. Skala · Morgridge Institute for Research
2016 · research · SU2C Innovative Research Grant (Class of 2016)
UNCOVERING HOW RAD51 PARALOG MUTATIONS CONTRIBUTE TO CANCER PREDISPOSITION
Kara A. Bernstein · University of Pittsburgh
2016–2020 · research · LAURA ZISKIN TRANSLATIONAL AWARD RESEARCH TEAM
Phosphatidylinositol 3-kinase δ Inhibition to Treat Patients With Relapsed or Refractory Follicular Lymphoma
Siddhartha Mukherjee · Columbia University
2016 · research · Phillip A. Sharp Innovation in Collaboration Award (Class of 2016)
DEFINING THE ROLE OF EPIGENETICS IN CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY FOR CLL
Shelley L. Berger
2016 · research · Phillip A. Sharp Innovation in Collaboration Award (Class of 2016)
CHECKPOINT INHIBITION IN CHILDREN WITH ULTRA- MUTATED CANCER DUE TO BIALLELIC MISMATCH REPAIR DEFICIENCY (BMMRD)
Crystal L. Mackall
2016 · research · Phillip A. Sharp Innovation in Collaboration Award (Class of 2016)
TOWARDS PREDICTIVE MODELS OF IMMUNOTHERAPY RESPONSE
Benjamin D. Greenbaum
2016 · research · SU2C Innovative Research Grant (Class of 2016)
DEFINING THE METABOLIC DEPENDENCIES OF TUMORS
Matthew Vander Heiden · Massachusetts Institute of Technology
2016 · research · Phillip A. Sharp Innovation in Collaboration Award (Class of 2016)
FUNCTIONAL VERIFICATION OF DNA REPAIR MUTATIONS IN PROSTATE AND OVARY TUMORS
Eliezer M. Van Allen
2016 · research · SU2C Innovative Research Grant (Class of 2016)
TARGETING CELLULAR PLASTICITY IN INDIVIDUAL BASAL-TYPE BREAST CANCER CELLS
John G. Albeck · University of California, Davis
2016 · research · SU2C Innovative Research Grant (Class of 2016)
METABOLIC REPROGRAMMING USING ONCOLYTIC VIRUSES TO IMPROVE IMMUNOTHERAPY
Greg M. Delgoffe · University of Pittsburgh
2016 · research · SU2C Innovative Research Grant (Class of 2016)
ALGORITHMICALLY DRIVEN QUANTITATIVE COMBINATION CANCER THERAPY ENGINEERING
Dan A. Landau · Weill Cornell Medicine
2016–2020 · research · SU2C–OVARIAN CANCER RESEARCH ALLIANCE– NATIONAL OVARIAN CANCER COALITION OVARIAN CANCER DREAM TEAM
DNA Repair Therapies for Ovarian Cancer
Alan D. D’Andrea · Mayo Clinic
2016 · research · Phillip A. Sharp Innovation in Collaboration Award (Class of 2016)
FINGERPRINTING THE SYSTEMIC MICROBIOME IN PLASMA TO PREDICT IMMUNOTHERAPY OUTCOMES IN MELANOMA
Muhammed Murtaza
2016 · research · SU2C Innovative Research Grant (Class of 2016)
PHOSPHOLIPID MESSENGERS AS DRIVERS OF DENDRITIC CELL DYSFUNCTION IN CANCER
Juan R. Cubillos-Ruiz · Weill Cornell Medicine
2016–2020 · research · SU2C–CANCER RESEARCH UK–LUSTGARTEN FOUNDATION PANCREATIC CANCER DREAM TEAM
Reprogramming of Transcriptional Circuitry to Control Pancreatic Cancer
Daniel D. Von Hoff · University of Cambridge
2016 · research · SU2C Innovative Research Grant (Class of 2016)
DEFINING THE MECHANISTIC CONNECTIONS BETWEEN INJURY, REGENERATION, AND CANCER
Hao Zhu · The University of Texas Southwestern Medical Center
2016 · research · SU2C Innovative Research Grant (Class of 2016)
“WEAK LINKS” IN CANCER PROTEOSTASIS NETWORKS AS NEW THERAPEUTIC TARGETS
Martin Kampmann · University of California, San Francisco
2015–2022 · research · SU2C–DUTCH CANCER SOCIETY COLORECTAL CANCER EARLY DETECTION DREAM TEAM
Molecular Early Detection of Colorectal Cancer (MEDOCC)
Gerrit A. Meijer · Maastricht University
2015–2020 · research · SU2C–NATIONAL SCIENCE FOUNDATION–LUSTGARTEN FOUNDATION CONVERGENCE™ RESEARCH TEAM
Liberating T-Cell Mediated Immunity to Pancreatic Cancer
Peter O’Dwyer · University of Pennsylvania
2015–2021 · research · SU2C–AMERICAN CANCER SOCIETY LUNG CANCER DREAM TEAM
Targeting KRAS-Mutant Lung Cancers
Jedd D. Wolchok · Johns Hopkins University
2014–2023 · research · SU2C–LUSTGARTEN FOUNDATION PANCREATIC CANCER DREAM TEAM
Transforming Pancreatic Cancer to Treatable Disease
Elizabeth M. Jaffee · Johns Hopkins University
2014–2020 · research · SU2C–FARRAH FAWCETT FOUNDATION HPV RESEARCH TEAM
Therapeutic CD8 Vaccines Against Conserved E7 HPV Epitopes Identified by MS
Ellis L. Reinherz · Dana-Farber Cancer Institute